Apollomics, Inc. Logo

Apollomics, Inc.

APLM

()
Stock Price

9,75 USD

-191.49% ROA

-184.11% ROE

-0.23x PER

Market Cap.

15.430.068,00 USD

21.43% DER

0% Yield

-2518.21% NPM

Apollomics, Inc. Stock Analysis

Apollomics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Apollomics, Inc. Fundamental Stock Analysis
# Analysis Rating

Apollomics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Apollomics, Inc. Technical Stock Analysis
# Analysis Recommendation

Apollomics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Apollomics, Inc. Revenue
Year Revenue Growth
2019 0
2020 1.838.000 100%
2021 2.000 -91800%
2022 323.000 99.38%
2023 821.000 60.66%
2024 3.870.000 78.79%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Apollomics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2019 18.442.000
2020 31.441.000 41.34%
2021 35.568.000 11.6%
2022 35.457.000 -0.31%
2023 34.193.000 -3.7%
2024 33.852.000 -1.01%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Apollomics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 0
2020 11.043.000 100%
2021 15.291.000 27.78%
2022 9.947.000 -53.72%
2023 20.641.000 51.81%
2024 20.306.000 -1.65%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Apollomics, Inc. EBITDA
Year EBITDA Growth
2019 -24.379.000
2020 -73.476.000 66.82%
2021 -91.070.000 19.32%
2022 -239.436.000 61.96%
2023 -54.834.000 -336.66%
2024 -50.218.000 -9.19%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Apollomics, Inc. Gross Profit
Year Gross Profit Growth
2019 -369.000
2020 1.229.000 130.02%
2021 -679.000 281%
2022 -452.000 -50.22%
2023 821.000 155.05%
2024 3.870.000 78.79%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Apollomics, Inc. Net Profit
Year Net Profit Growth
2019 -45.905.000
2020 -74.820.000 38.65%
2021 -94.797.000 21.07%
2022 -240.811.000 60.63%
2023 -172.601.000 -39.52%
2024 -70.412.000 -145.13%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Apollomics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -1
2020 -1 0%
2021 -1 100%
2022 -3 50%
2023 -2 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Apollomics, Inc. Free Cashflow
Year Free Cashflow Growth
2019 -22.800.000
2020 -45.825.000 50.25%
2021 -50.862.000 9.9%
2022 -43.191.000 -17.76%
2023 -43.215.000 0.06%
2024 -8.006.000 -439.78%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Apollomics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2019 -21.943.000
2020 -35.681.000 38.5%
2021 -43.312.000 17.62%
2022 -42.824.000 -1.14%
2023 -43.209.000 0.89%
2024 -7.994.000 -440.52%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Apollomics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2019 857.000
2020 10.144.000 91.55%
2021 7.550.000 -34.36%
2022 367.000 -1957.22%
2023 6.000 -6016.67%
2024 12.000 50%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Apollomics, Inc. Equity
Year Equity Growth
2019 -60.722.000
2020 -127.933.000 52.54%
2021 -212.862.000 39.9%
2022 -448.120.000 52.5%
2023 41.234.000 1186.77%
2023 55.697.000 25.97%
2024 20.807.000 -167.68%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Apollomics, Inc. Assets
Year Assets Growth
2019 79.053.000
2020 169.941.000 53.48%
2021 123.437.000 -37.67%
2022 76.475.000 -61.41%
2023 55.387.000 -38.07%
2023 71.378.000 22.4%
2024 34.573.000 -106.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Apollomics, Inc. Liabilities
Year Liabilities Growth
2019 139.775.000
2020 297.874.000 53.08%
2021 336.299.000 11.43%
2022 524.595.000 35.89%
2023 14.153.000 -3606.6%
2023 15.681.000 9.74%
2024 13.766.000 -13.91%

Apollomics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.02
Net Income per Share
-0.62
Price to Earning Ratio
-0.23x
Price To Sales Ratio
6.8x
POCF Ratio
-0.38
PFCF Ratio
-0.44
Price to Book Ratio
0.63
EV to Sales
-2.66
EV Over EBITDA
0.11
EV to Operating CashFlow
0.17
EV to FreeCashFlow
0.17
Earnings Yield
-4.34
FreeCashFlow Yield
-2.26
Market Cap
0,02 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
1.76
Graham NetNet
0.13

Income Statement Metrics

Net Income per Share
-0.62
Income Quality
0.61
ROE
-1.84
Return On Assets
-1.65
Return On Capital Employed
-2.42
Net Income per EBT
1
EBT Per Ebit
1.08
Ebit per Revenue
-23.37
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
9.32
Research & Developement to Revenue
15.26
Stock Based Compensation to Revenue
3.26
Gross Profit Margin
1
Operating Profit Margin
-23.37
Pretax Profit Margin
-25.18
Net Profit Margin
-25.18

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.38
Free CashFlow per Share
-0.38
Capex to Operating CashFlow
-0
Capex to Revenue
0.01
Capex to Depreciation
0.05
Return on Invested Capital
-2.1
Return on Tangible Assets
-1.91
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,28
Book Value per Share
0,22
Tangible Book Value per Share
0.17
Shareholders Equity per Share
0.22
Interest Debt per Share
0.05
Debt to Equity
0.21
Debt to Assets
0.13
Net Debt to EBITDA
0.41
Current Ratio
2.25
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
21811000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.14
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Apollomics, Inc. Dividends
Year Dividends Growth

Apollomics, Inc. Profile

About Apollomics, Inc.

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

CEO
Dr. Guo-Liang Yu Ph.D.
Employee
45
Address
989 East Hillsdale Blvd
Foster City, 94404

Apollomics, Inc. Executives & BODs

Apollomics, Inc. Executives & BODs
# Name Age
1 Dr. Matthew James Plunkett Ph.D.
Chief Financial Officer
70
2 Dr. Guo-Liang Yu Ph.D.
Co-Founder, Chief Executive Officer & Executive Chairman
70

Apollomics, Inc. Competitors